Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277352 · ClinicalTrials.gov registry record · Phase 1
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
A Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
- Terminated
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT03277352: Clinical Trial Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
NCT03277352 is a Phase 1 study that was terminated before completion, run by Incyte Biosciences International Sàrl. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03277352, a Phase 1 study, was terminated before completion, sponsored by Incyte Biosciences International Sàrl.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
Primary Outcome
A TEAE is any adverse event (AE) either reported for the first time or worsening of a pre-existing event after the first dose of study treatment.
Interventions
- DRUG Pembrolizumab
- DRUG Epacadostat
- DRUG INCAGN01876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2017-11-21 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 1 |
Why NCT03277352 stopped before completion
NCT03277352 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT03277352 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03277352 about?
NCT03277352 is a clinical study titled "INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies". The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.
What is the current status of trial NCT03277352?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2017-11-21. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT03277352?
The interventions under investigation include: Pembrolizumab (DRUG), Epacadostat (DRUG), INCAGN01876 (DRUG).
Who is sponsoring clinical trial NCT03277352?
This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03277352's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI